Skip to main content
ARS Home » Northeast Area » Beltsville, Maryland (BARC) » Beltsville Agricultural Research Center » Animal Biosciences & Biotechnology Laboratory » Research » Publications at this Location » Publication #305357


Location: Animal Biosciences & Biotechnology Laboratory

Title: Triple-acting antimicrobial treatment for drug-resistant and intracellular Staphylococcus aureus.

item Becker, Stephen
item Roach, Dwayne
item CHAUNHAN, VINITA - University Of North Carolina
item SHEN, YANG - University Of Maryland
item Foster Frey, Juli
item Powell, Anne
item BUCHANNAN, GARY - US Department Of Agriculture (USDA)
item LEASE, RICHARD - The Ohio State University
item Mohammadi, Homan
item Harty, William
item Simmons, Chad
item Camp, Mary
item SHIELDS, KELLY - Harvard Medical School
item DOWD, MEGAN - University Of Alabama
item DONG, SHENGLI - University Of Alabama
item BAKER, JOHN - University Of Alabama
item SHEEN, TAMSIN - San Diego State University
item DORAN, KELLY - San Diego State University
item PRITCHARD, DAVID - Alabama State University
item ALMEIDA, RAUL - University Of Tennessee
item NELSON, DANIEL - University Of Maryland
item MARRIOTT, IAN - University Of North Carolina
item LEE, JEAN - Harvard Medical School
item Donovan, David

Submitted to: Meeting Abstract
Publication Type: Abstract Only
Publication Acceptance Date: 5/21/2014
Publication Date: N/A
Citation: N/A

Interpretive Summary:

Technical Abstract: Multi-drug resistant bacteria are a persistent problem in modern health care, food safety and animal health. There is a need for new antimicrobials to replace over-used conventional antibiotics. Staphylococcus aureus (S. aureus) is a notorious pathogen for both animal and human health with multi-drug resistant strains highly prevalent. This pathogen has also evolved another way to evade antibiotic treatment by invading and residing intracellularly within animal cells. New treatments that reduce resistance development and tackle intracellular pathogens are sorely needed. We have identified three enzyme activities that cut the cell wall structural element (peptidoglycan) of S. aureus in three unique regions. Any one of the three enzymatic activities can kill the cells when exposed externally. When fused these three enzyme domains maintain each of their activities in the final triple-acting fusion. We have shown that these triple-acting enzyme constructs greatly reduce resistance development compared to the parental enzymes alone and are effective at reducing S. aureus nasal colonization by 97%. We also show that when these enzymes (single, double or triple domain harboring) are fused to protein transduction domains, they can enter animal cells and reduce the intracellular load of the pathogen up to 97% in three different cell types from three different species. The effect is maintained in two different animal models (osteomyelitis and mastitis of mice) as well as staphylococcal biofilms. The findings of this work identify the necessary components and methodology for generating multiple domain fusions with elements to address intracellular and multi-drug resistant pathogens. These findings will aid scientists in the development of these and similar molecules as commercializable antimicrobials for use in animal production, animal and human health and food safety.